

Scott D Berkowitz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6906787/publications.pdf>

Version: 2024-02-01

172
papers

28,819
citations

17440

63
h-index

4991

167
g-index

183
all docs

183
docs citations

183
times ranked

17562
citing authors

#	ARTICLE	IF	CITATIONS
1	Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation. New England Journal of Medicine, 2011, 365, 883-891.	27.0	8,006
2	Oral Rivaroxaban for Symptomatic Venous Thromboembolism. New England Journal of Medicine, 2010, 363, 2499-2510.	27.0	2,807
3	Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism. New England Journal of Medicine, 2012, 366, 1287-1297.	27.0	2,080
4	Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. New England Journal of Medicine, 2017, 377, 1319-1330.	27.0	1,745
5	Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet, The, 2009, 373, 1673-1680.	13.7	898
6	Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source. New England Journal of Medicine, 2018, 378, 2191-2201.	27.0	730
7	Argatroban Anticoagulant Therapy in Patients With Heparin-Induced Thrombocytopenia. Circulation, 2001, 103, 1838-1843.	1.6	661
8	Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism. New England Journal of Medicine, 2017, 376, 1211-1222.	27.0	577
9	Rivaroxaban in Peripheral Artery Disease after Revascularization. New England Journal of Medicine, 2020, 382, 1994-2004.	27.0	566
10	Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thrombosis Journal, 2013, 11, 21.	2.1	471
11	Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet, The, 2018, 391, 205-218.	13.7	426
12	Comparison of Ximelagatran with Warfarin for the Prevention of Venous Thromboembolism after Total Knee Replacement. New England Journal of Medicine, 2003, 349, 1703-1712.	27.0	317
13	Ximelagatran vs Low-Molecular-Weight Heparin and Warfarin for the Treatment of Deep Vein Thrombosis. JAMA - Journal of the American Medical Association, 2005, 293, 681.	7.4	274
14	Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF Trial. European Heart Journal, 2015, 36, 288-296.	2.2	266
15	Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Thrombosis and Haemostasis, 2011, 105, 444-453.	3.4	250
16	Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials. Lancet Haematology, the, 2014, 1, e37-e46.	4.6	244
17	Factors Associated With Major Bleeding Events. Journal of the American College of Cardiology, 2014, 63, 891-900.	2.8	212
18	Allogeneic Blood Transfusions and Postoperative Infections After Total Hip or Knee Arthroplasty. Journal of Bone and Joint Surgery - Series A, 2014, 96, 272-278.	3.0	197

#	ARTICLE	IF	CITATIONS
19	Incidence and Predictors of Bleeding After Contemporary Thrombolytic Therapy for Myocardial Infarction. <i>Circulation</i> , 1997, 95, 2508-2516.	1.6	194
20	Acute Profound Thrombocytopenia After c7E3 Fab (Abciximab) Therapy. <i>Circulation</i> , 1997, 95, 809-813.	1.6	193
21	Ximelagatran versus Warfarin for the Prevention of Venous Thromboembolism after Total Knee Arthroplasty. <i>Annals of Internal Medicine</i> , 2002, 137, 648.	3.9	187
22	Intracranial Hemorrhage Among Patients With Atrial Fibrillation Anticoagulated With Warfarin or Rivaroxaban. <i>Stroke</i> , 2014, 45, 1304-1312.	2.0	187
23	Outcomes of Discontinuing Rivaroxaban Compared With Warfarin in Patients With Nonvalvular Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2013, 61, 651-658.	2.8	181
24	Comparison of three- and four-factor prothrombin complex concentrates regarding reversal of the anticoagulant effects of rivaroxaban in healthy volunteers. <i>Journal of Thrombosis and Haemostasis</i> , 2014, 12, 1428-1436.	3.8	181
25	Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial. <i>Lancet Haematology</i> , 2020, 7, e18-e27.	4.6	173
26	Cardiovascular Drug Development. <i>Journal of the American College of Cardiology</i> , 2015, 65, 1567-1582.	2.8	168
27	Economic Assessment of Low-Molecular-Weight Heparin (Enoxaparin) Versus Unfractionated Heparin in Acute Coronary Syndrome Patients. <i>Circulation</i> , 1998, 97, 1702-1707.	1.6	163
28	Complication Rates After Hip or Knee Arthroplasty in Morbidly Obese Patients. <i>Clinical Orthopaedics and Related Research</i> , 2013, 471, 3358-3366.	1.5	160
29	Gastrointestinal Bleeding in Patients With Atrial Fibrillation Treated With Rivaroxaban or Warfarin. <i>Journal of the American College of Cardiology</i> , 2015, 66, 2271-2281.	2.8	159
30	Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial. <i>European Heart Journal</i> , 2014, 35, 3377-3385.	2.2	154
31	Comparison of the Oral Direct Thrombin Inhibitor Ximelagatran With Enoxaparin as Prophylaxis Against Venous Thromboembolism After Total Knee Replacement. <i>Archives of Internal Medicine</i> , 2001, 161, 2215.	3.8	150
32	Recurrent Stroke With Rivaroxaban Compared With Aspirin According to Predictors of Atrial Fibrillation. <i>JAMA Neurology</i> , 2019, 76, 764.	9.0	147
33	Clinical Significance of Thrombocytopenia During a Non-ST-Elevation Acute Coronary Syndrome. <i>Circulation</i> , 1999, 99, 2892-2900.	1.6	146
34	Rivaroxaban or aspirin for patent foramen ovale and embolic stroke of undetermined source: a prespecified subgroup analysis from the NAVIGATE ESUS trial. <i>Lancet Neurology</i> , 2018, 17, 1053-1060.	10.2	146
35	Effect of Osocimab in Preventing Venous Thromboembolism Among Patients Undergoing Knee Arthroplasty. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 130.	7.4	146
36	Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trial. <i>European Heart Journal</i> , 2014, 35, 1873-1880.	2.2	145

#	ARTICLE	IF	CITATIONS
37	Rivaroxaban for Stroke Prevention in East Asian Patients From the ROCKET AF Trial. <i>Stroke</i> , 2014, 45, 1739-1747.	2.0	142
38	Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization. <i>Journal of the American College of Cardiology</i> , 1998, 32, 311-319.	2.8	141
39	Comparison of ximelagatran, an oral direct thrombin inhibitor, with enoxaparin for the prevention of venous thromboembolism following total hip replacement. A randomized, double-blind study. <i>Journal of Thrombosis and Haemostasis</i> , 2003, 1, 2119-2130.	3.8	141
40	Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation. <i>Circulation</i> , 2016, 133, 352-360.	1.6	141
41	On-Treatment Outcomes in Patients With Worsening Renal Function With Rivaroxaban Compared With Warfarin. <i>Circulation</i> , 2016, 134, 37-47.	1.6	134
42	Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: The Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial). <i>American Heart Journal</i> , 2015, 170, 675-682.e8.	2.7	128
43	Cause of Death and Predictors of All-cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF. <i>Journal of the American Heart Association</i> , 2016, 5, e002197.	3.7	127
44	Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). <i>Lancet</i> , The, 2015, 385, 2363-2370.	13.7	123
45	Stroke Outcomes in the COMPASS Trial. <i>Circulation</i> , 2019, 139, 1134-1145.	1.6	118
46	Glycoprotein IIb/IIIa Integrin Blockade. <i>Circulation</i> , 1998, 98, 2629-2635.	1.6	117
47	Embolic strokes of undetermined source: Prevalence and patient features in the ESUS Global Registry. <i>International Journal of Stroke</i> , 2016, 11, 526-533.	5.9	113
48	Rationale and design for the Vascular Outcomes study of ASA along with rivaroxaban in endovascular or surgical limb revascularization for peripheral artery disease (VOYAGER PAD). <i>American Heart Journal</i> , 2018, 199, 83-91.	2.7	104
49	Efficacy and Safety of Rivaroxaban in Patients With Heart Failure and Nonvalvular Atrial Fibrillation. <i>Circulation: Heart Failure</i> , 2013, 6, 740-747.	3.9	102
50	Evaluation of Drug-Induced Serious Hepatotoxicity (eDISH). <i>Drug Safety</i> , 2011, 34, 243-252.	3.2	98
51	Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes Mellitus and Cardiovascular Disease. <i>Circulation</i> , 2020, 141, 1841-1854.	1.6	96
52	Efficacy and Safety of Low Molecular Weight Heparin (Ardeparin Sodium) Compared to Warfarin for the Prevention of Venous Thromboembolism after Total Knee Replacement Surgery: A Double-blind, Dose-ranging Study. <i>Thrombosis and Haemostasis</i> , 1997, 77, 032-038.	3.4	96
53	Relationship Between Time in Therapeutic Range and Comparative Treatment Effect of Rivaroxaban and Warfarin: Results From the ROCKET AF Trial. <i>Journal of the American Heart Association</i> , 2014, 3, e000521.	3.7	94
54	Clinical correlates and course of thrombocytopenia during percutaneous coronary intervention in the era of abciximab platelet glycoprotein IIb/IIIa blockade. <i>American Heart Journal</i> , 2000, 140, 74-80.	2.7	83

#	ARTICLE	IF	CITATIONS
55	Rivaroxaban for secondary stroke prevention in patients with embolic strokes of undetermined source: Design of the NAVIGATE ESUS randomized trial. <i>European Stroke Journal</i> , 2016, 1, 146-154.	5.5	83
56	Modifiable Risk Factors for Vascular Access Site Complications in the IMPACT II Trial of Angioplasty With Versus Without Eptifibatide. <i>Journal of the American College of Cardiology</i> , 1998, 31, 1518-1524.	2.8	80
57	Aortic Arch Atherosclerosis in Patients With Embolic Stroke of Undetermined Source. <i>Stroke</i> , 2019, 50, 3184-3190.	2.0	78
58	Efficacy and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and a history of cancer: observations from ROCKET AF. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2019, 5, 145-152.	4.0	75
59	Relation of Risk of Stroke in Patients With Atrial Fibrillation to Body Mass Index (from Patients) Tj ETQq1 1 0.784314 rgBT /Overlock 10	1.6	74
60	Efficacy and Safety of Rivaroxaban Versus Aspirin in Embolic Stroke of Undetermined Source and Carotid Atherosclerosis. <i>Stroke</i> , 2019, 50, 2477-2485.	2.0	72
61	Novel oral anticoagulants and reversal agents: Considerations for clinical development. <i>American Heart Journal</i> , 2015, 169, 751-757.	2.7	69
62	Rapid assessment of glycoprotein IIb/IIIa blockade with the platelet function analyzer (PFA-100) during percutaneous coronary intervention. <i>American Heart Journal</i> , 2001, 141, 226-233.	2.7	68
63	Is thrombosis a contributor to heart failure pathophysiology? Possible mechanisms, therapeutic opportunities, and clinical investigation challenges. <i>International Journal of Cardiology</i> , 2013, 167, 1772-1782.	1.7	67
64	Understanding thrombocytopenia and antigenicity with glycoprotein IIb-IIIa inhibitors. <i>American Heart Journal</i> , 1999, 138, S317-S326.	2.7	59
65	Rivaroxaban and Aspirin in Peripheral Artery Disease Lower Extremity Revascularization. <i>Circulation</i> , 2020, 142, 2219-2230.	1.6	58
66	Potential Embolic Sources and Outcomes in Embolic Stroke of Undetermined Source in the NAVIGATE-ESUS Trial. <i>Stroke</i> , 2020, 51, 1797-1804.	2.0	54
67	Use and outcomes of antiarrhythmic therapy in patients with atrial fibrillation receiving oral anticoagulation: Results from the ROCKET AF trial. <i>Heart Rhythm</i> , 2014, 11, 925-932.	0.7	52
68	Rivaroxaban for treatment of pediatric venous thromboembolism. An Einsteinâ€r phase 3 doseâ€r exposureâ€r response evaluation. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 1672-1685.	3.8	52
69	Use of concomitant aspirin in patients with atrial fibrillation: Findings from the ROCKET AF trial. <i>American Heart Journal</i> , 2016, 179, 77-86.	2.7	51
70	Safety and efficacy of rivaroxaban in pediatric cerebral venous thrombosis (EINSTEIN-Jr CVT). <i>Blood Advances</i> , 2020, 4, 6250-6258.	5.2	49
71	Efficacy of abciximab readministration in coronary intervention. <i>American Journal of Cardiology</i> , 2000, 85, 435-440.	1.6	48
72	Blood pressure control and stroke or bleeding risk in anticoagulated patients with atrial fibrillation: Results from the ROCKET AF Trial. <i>American Heart Journal</i> , 2016, 178, 74-84.	2.7	48

#	ARTICLE	IF	CITATIONS
73	Oral Direct Thrombin Inhibitor Ximelagatran Compared with Warfarin for the Prevention of Venous Thromboembolism After Total Knee Arthroplasty. <i>Journal of Bone and Joint Surgery - Series A</i> , 2005, 87, 2169.	3.0	47
74	Oral heparin administration with a novel drug delivery agent (SNAC) in healthy volunteers and patients undergoing elective total hip arthroplasty. <i>Journal of Thrombosis and Haemostasis</i> , 2003, 1, 1914-1919.	3.8	46
75	Clinical Outcomes With Rivaroxaban in Patients Transitioned From Vitamin K Antagonist Therapy. <i>Annals of Internal Medicine</i> , 2013, 158, 861.	3.9	46
76	Characterization of Patients with Embolic Strokes of Undetermined Source in the NAVIGATE ESUS Randomized Trial. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2018, 27, 1673-1682.	1.6	46
77	The effects of rivaroxaban on the complications of surgery after total hip or knee replacement. <i>Journal of Bone and Joint Surgery: British Volume</i> , 2012, 94-B, 1573-1578.	3.4	43
78	End of Study Transition From Study Drug to Open-Label Vitamin K Antagonist Therapy. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2013, 6, 470-478.	2.2	39
79	Rivaroxaban Plus Aspirin Versus Aspirin Alone in Patients With Prior Percutaneous Coronary Intervention (COMPASS-PCI). <i>Circulation</i> , 2020, 141, 1141-1151.	1.6	39
80	Hemodilution With Other Blood Reinfusion Techniques in Total Hip Arthroplasty. <i>Clinical Orthopaedics and Related Research</i> , 1997, 339, 132-139.	1.5	38
81	Characteristics of Recurrent Ischemic Stroke After Embolic Stroke of Undetermined Source. <i>JAMA Neurology</i> , 2020, 77, 1233.	9.0	37
82	Determination of platelet aggregation inhibition during percutaneous coronary intervention with the platelet function analyzer PFA-100. <i>American Heart Journal</i> , 2002, 144, 151-158.	2.7	36
83	Native valve disease in patients with non-valvular atrial fibrillation on warfarin or rivaroxaban. <i>Heart</i> , 2016, 102, 1036-1043.	2.9	36
84	Efficacy and Safety of Rivaroxaban Versus Warfarin in Patients Taking Nondihydropyridine Calcium Channel Blockers for Atrial Fibrillation (from the ROCKET AF Trial). <i>American Journal of Cardiology</i> , 2017, 120, 588-594.	1.6	36
85	Is there a role for pharmacokinetic/pharmacodynamic-guided dosing for novel oral anticoagulants?. <i>American Heart Journal</i> , 2018, 199, 59-67.	2.7	36
86	Bleeding and New Cancer Diagnosis in Patients With Atherosclerosis. <i>Circulation</i> , 2019, 140, 1451-1459.	1.6	36
87	Safety and efficacy of anticoagulant therapy in pediatric catheter-related venous thrombosis (EINSTEIN-Jr CVC-VTE). <i>Blood Advances</i> , 2020, 4, 4632-4639.	5.2	35
88	Estimating individual lifetime benefit and bleeding risk of adding rivaroxaban to aspirin for patients with stable cardiovascular disease: results from the COMPASS trial. <i>European Heart Journal</i> , 2019, 40, 3771-3778a.	2.2	34
89	Prospective comparison of hemorrhagic complications after treatment with enoxaparin versus unfractionated heparin for unstable angina pectoris or non-“ST-segment elevation acute myocardial infarction. <i>American Journal of Cardiology</i> , 2001, 88, 1230-1234.	1.6	33
90	Incidence of neuraxial haematoma after total hip or knee surgery: <scp>RECORD</scp> programme (rivaroxaban vs. enoxaparin). <i>Acta Anaesthesiologica Scandinavica</i> , 2013, 57, 565-572.	1.6	33

#	ARTICLE	IF	CITATIONS
91	Rivaroxaban and Aspirin in Patients With Symptomatic Lower Extremity Peripheral Artery Disease. JAMA Cardiology, 2021, 6, 21-29.	6.1	33
92	The determinants of activated partial thromboplastin time, relation of activated partial thromboplastin time to clinical outcomes, and optimal dosing regimens for heparin treated patients with acute coronary syndromes: a review of GUSTO-IIb. Journal of Thrombosis and Thrombolysis, 2002, 14, 91-101.	2.1	31
93	Hospitalizations in patients with atrial fibrillation: an analysis from ROCKET AF. Europace, 2016, 18, 1135-1142.	1.7	31
94	Mortality Benefit of Rivaroxaban Plus Aspirin in Patients With Chronic Coronary or Peripheral Artery Disease. Journal of the American College of Cardiology, 2021, 78, 14-23.	2.8	31
95	New heparin dosing recommendations for patients with acute coronary syndromes. American Journal of Medicine, 2001, 110, 641-650.	1.5	30
96	Treatment Consistency Across Levels of Baseline Renal Function With Rivaroxaban or Warfarin. Circulation, 2017, 135, 1001-1003.	1.6	30
97	Major Bleeding in Patients With Coronary or Peripheral Artery Disease Treated With Rivaroxaban Plus Aspirin. Journal of the American College of Cardiology, 2019, 74, 1519-1528.	2.8	30
98	Total Ischemic Event Reduction With Rivaroxaban After Peripheral Arterial Revascularization in the VOYAGER PAD Trial. Journal of the American College of Cardiology, 2021, 78, 317-326.	2.8	30
99	Heparin dosing and outcome in acute coronary syndromes: The GUSTO-IIb experience. American Heart Journal, 2002, 144, 73-80.	2.7	28
100	Benefit–risk assessment of rivaroxaban versus enoxaparin for the prevention of venous thromboembolism after total hip or knee arthroplasty. Vascular Health and Risk Management, 2014, 10, 157.	2.3	28
101	Evidence-Based Development and Rationale for Once-Daily Rivaroxaban Dosing Regimens Across Multiple Indications. Clinical and Applied Thrombosis/Hemostasis, 2016, 22, 412-422.	1.7	28
102	Rivaroxaban versus standard anticoagulation for acute venous thromboembolism in childhood. Design of the EINSTEIN-Jr phase III study. Thrombosis Journal, 2018, 16, 34.	2.1	28
103	Risk factors and clinical outcomes in chronic coronary and peripheral artery disease: An analysis of the randomized, double-blind COMPASS trial. European Journal of Preventive Cardiology, 2020, 27, 296-307.	1.8	28
104	Microbleeds and the Effect of Anticoagulation in Patients With Embolic Stroke of Undetermined Source. JAMA Neurology, 2021, 78, 11.	9.0	28
105	The discovery and development of rivaroxaban. Annals of the New York Academy of Sciences, 2011, 1222, 64-75.	3.8	27
106	Predictors of Recurrent Ischemic Stroke in Patients with Embolic Strokes of Undetermined Source and Effects of Rivaroxaban Versus Aspirin According to Risk Status: The NAVIGATE ESUS Trial. Journal of Stroke and Cerebrovascular Diseases, 2019, 28, 2273-2279.	1.6	27
107	Bleeding complications with platelet glycoprotein IIb/IIIa receptor antagonists. Current Opinion in Hematology, 1999, 6, 334-341.	2.5	26
108	Atrial Cardiopathy and Nonstenosing Large Artery Plaque in Patients With Embolic Stroke of Undetermined Source. Stroke, 2020, 51, 938-943.	2.0	25

#	ARTICLE	IF	CITATIONS
109	Rivaroxaban versus aspirin for secondary prevention of ischaemic stroke in patients with cancer: a subgroup analysis of the NAVIGATE ESUS randomized trial. <i>European Journal of Neurology</i> , 2020, 27, 841-848.	3.3	25
110	Effect of Rivaroxaban and Aspirin in Patients With Peripheral Artery Disease Undergoing Surgical Revascularization: Insights From the VOYAGER PAD Trial. <i>Circulation</i> , 2021, 144, 1104-1116.	1.6	25
111	Relation between inhibition of platelet aggregation and clinical outcomes. <i>American Heart Journal</i> , 1998, 136, s43-s50.	2.7	24
112	ORAL DIRECT THROMBIN INHIBITOR XIMELAGATRAN COMPARED WITH WARFARIN FOR THE PREVENTION OF VENOUS THROMBOEMBOLISM AFTER TOTAL KNEE ARTHROPLASTY. <i>Journal of Bone and Joint Surgery - Series A</i> , 2005, 87, 2169-2177.	3.0	24
113	Comparison of two aspirin doses on ischemic stroke in post-myocardial infarction patients in the warfarin (Coumadin) Aspirin Reinfarction Study (CARS). <i>American Journal of Cardiology</i> , 2001, 88, 541-546.	1.6	23
114	Branch atheromatous disease diagnosed as embolic stroke of undetermined source: A sub-analysis of NAVIGATE ESUS. <i>International Journal of Stroke</i> , 2019, 14, 915-922.	5.9	22
115	Use of Dual Antiplatelet Therapy and Patient Outcomes in Those Undergoing Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 1694-1702.	2.9	21
116	Selective Serotonin Reuptake Inhibitors and Bleeding Risk in Anticoagulated Patients With Atrial Fibrillation: An Analysis From the ROCKET AF Trial. <i>Journal of the American Heart Association</i> , 2018, 7, e008755.	3.7	21
117	Reduction in Acute Limb Ischemia With Rivaroxaban Versus Placebo in Peripheral Artery Disease After Lower Extremity Revascularization: Insights From VOYAGER PAD. <i>Circulation</i> , 2021, 144, 1831-1841.	1.6	19
118	Safety and Effectiveness of Paclitaxel Drug-Coated Devices in Peripheral Artery Revascularization. <i>Journal of the American College of Cardiology</i> , 2021, 78, 1768-1778.	2.8	19
119	Rivaroxaban: a novel oral anticoagulant for the prevention and treatment of several thrombotic-mediated conditions. <i>Annals of the New York Academy of Sciences</i> , 2013, 1291, 42-55.	3.8	18
120	High-Sensitivity Cardiac Troponin T for Risk Stratification in Patients With Embolic Stroke of Undetermined Source. <i>Stroke</i> , 2020, 51, 2386-2394.	2.0	18
121	Low-dose rivaroxaban and aspirin among patients with peripheral artery disease: a meta-analysis of the COMPASS and VOYAGER trials. <i>European Journal of Preventive Cardiology</i> , 2022, 29, e181-e189.	1.8	18
122	Coagulation complicating cardiopulmonary bypass in a patient with heparin-induced thrombocytopenia receiving the heparinoid, danaparoid sodium. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 1997, 11, 875-877.	1.3	17
123	Intracranial and systemic atherosclerosis in the NAVIGATE ESUS trial: Recurrent stroke risk and response to antithrombotic therapy. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2020, 29, 104936.	1.6	17
124	The discovery of rivaroxaban: translating preclinical assessments into clinical practice. <i>Frontiers in Pharmacology</i> , 2013, 4, 145.	3.5	15
125	Rivaroxaban for Prevention of Covert Brain Infarcts and Cognitive Decline. <i>Stroke</i> , 2020, 51, 2901-2909.	2.0	15
126	Efficacy and safety of rivaroxaban plus aspirin in women and men with chronic coronary or peripheral artery disease. <i>Cardiovascular Research</i> , 2021, 117, 942-949.	3.8	15

#	ARTICLE	IF	CITATIONS
127	Progress in point-of-care laboratory testing for assessing platelet function. American Heart Journal, 1998, 136, s51-s65.	2.7	14
128	Clinical presentation and therapeutic management of venous thrombosis in young children: a retrospective analysis. Thrombosis Journal, 2018, 16, 29.	2.1	14
129	Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in patients with non-valvular atrial fibrillation. Journal of Thrombosis and Thrombolysis, 2020, 50, 20-29.	2.1	14
130	Antithrombotic therapy after prosthetic cardiac valve implantation: Potential novel antithrombotic therapies. American Heart Journal, 2001, 142, 7-13.	2.7	13
131	Low-dose rivaroxaban plus aspirin in older patients with peripheral artery disease undergoing acute limb revascularization: insights from the VOYAGER PAD trial. European Heart Journal, 2021, 42, 4040-4048.	2.2	13
132	Efficacy and safety of rivaroxaban versus warfarin in patients from mainland China with nonvalvular atrial fibrillation: A subgroup analysis from the ROCKET AF trial. Thrombosis Research, 2017, 156, 184-190.	1.7	11
133	Efficacy and safety of rivaroxaban compared with warfarin in patients with carotid artery disease and nonvalvular atrial fibrillation: Insights from the ROCKET AF trial. Clinical Cardiology, 2018, 41, 39-45.	1.8	11
134	Rationale, design, and baseline participant characteristics in the MRI and cognitive substudy of the cardiovascular outcomes for people using anticoagulation strategies trial. International Journal of Stroke, 2019, 14, 270-281.	5.9	11
135	Rivaroxaban Plus Aspirin in Obese and Overweight Patients With Vascular Disease in the COMPASS Trial. Journal of the American College of Cardiology, 2021, 77, 511-525.	2.8	11
136	Rivaroxaban and Risk of Venous Thromboembolism in Patients With Symptomatic Peripheral Artery Disease After Lower Extremity Revascularization. JAMA Network Open, 2022, 5, e2215580.	5.9	11
137	Outcome of Patients Receiving Thrombolytic Therapy While on Rivaroxaban for Nonvalvular Atrial Fibrillation (from Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K) Tj ETQq1 1 0.784314 rgBT /Overbo Cardiology, 2017, 120, 1837-1840.	1.6	10
138	Net clinical benefit of rivaroxaban compared with warfarin in atrial fibrillation: Results from ROCKET AF. International Journal of Cardiology, 2018, 257, 78-83.	1.7	10
139	Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in the treatment of venous thromboembolism. Journal of Thrombosis and Thrombolysis, 2020, 50, 1-11.	2.1	10
140	Antithrombotic outcome trials in acute coronary syndromes: seeking the optimal balance between safety and efficacyâ€. European Heart Journal, 2013, 34, 1621-1629.	2.2	9
141	Enhancing the Quality of Rivaroxaban Exposure Estimates Using Prothrombin Time in the Absence of Pharmacokinetic Sampling. CPT: Pharmacometrics and Systems Pharmacology, 2019, 8, 805-814.	2.5	9
142	Once-Daily Oral Rivaroxaban Compared with Subcutaneous Enoxaparin Every 12 Hours for Thromboprophylaxis after Total Knee Replacement: RECORD4. Blood, 2008, 112, 35-35.	1.4	9
143	Safety and Efficacy of Rivaroxaban in Patients With Cardiac Implantable Electronic Devices: Observations From the ROCKET AF Trial. Journal of the American Heart Association, 2017, 6, .	3.7	8
144	Frequency and Patterns of Brain Infarction in Patients With Embolic Stroke of Undetermined Source: NAVIGATE ESUS Trial. Stroke, 2022, 53, 45-52.	2.0	8

#	ARTICLE	IF	CITATIONS
145	Effects of Age, Weight, Gender and Renal Function in a Pooled Analysis of Four Phase III Studies of Rivaroxaban for Prevention of Venous Thromboembolism after Major Orthopedic Surgery. <i>Blood</i> , 2008, 112, 436-436.	1.4	8
146	Rivaroxaban versus aspirin for prevention of covert brain infarcts in patients with embolic stroke of undetermined source: NAVIGATE ESUS MRI substudy. <i>International Journal of Stroke</i> , 2022, 17, 799-805.	5.9	8
147	Sex-Based Differences in Outcomes Following Peripheral Artery Revascularization: Insights From VOYAGER PAD. <i>Journal of the American Heart Association</i> , 2022, 11, .	3.7	8
148	Frequency and Predictors of Major Bleeding in Patients With Embolic Strokes of Undetermined Source. <i>Stroke</i> , 2020, 51, 2139-2147.	2.0	7
149	Current Knowledge of the Platelet Glycoprotein IIb/IIIa Receptor Antagonists for the Treatment of Coronary Artery Disease. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , 2000, 30, 27-43.	0.3	6
150	Impact of polyvascular disease on patients with atrial fibrillation: Insights from ROCKET AF. <i>American Heart Journal</i> , 2018, 200, 102-109.	2.7	6
151	Influence of model-predicted rivaroxaban exposure and patient characteristics on efficacy and safety outcomes in patients with acute coronary syndrome. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2019, 13, 175394471986364.	2.1	6
152	Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in the prevention of venous thromboembolism. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 50, 12-19.	2.1	6
153	Cardiovascular consequences of discontinuing low-dose rivaroxaban in people with chronic coronary or peripheral artery disease. <i>Heart</i> , 2021, 107, 1130-1137.	2.9	6
154	TREATMENT OF ESTABLISHED DEEP VEIN THROMBOSIS: A REVIEW OF THE THERAPEUTIC ARMAMENTARIUM. <i>Orthopedics</i> , 1995, 18, 18-20.	1.1	5
155	Thrombin and fibrin activity in patients treated with enoxaparin, ticlopidine and aspirin versus the conventional coumadin regimen after elective stenting: The ENTICES trial. <i>Journal of the American College of Cardiology</i> , 1996, 27, 334.	2.8	4
156	Rivaroxaban versus warfarin in patients with atrial fibrillation enrolled in Latin America: Insights from ROCKET AF. <i>American Heart Journal</i> , 2021, 236, 4-12.	2.7	4
157	Risk stratification of cardiovascular complications using CHA2DS2-VASc and CHADS2 scores in chronic atherosclerotic cardiovascular disease. <i>International Journal of Cardiology</i> , 2021, 337, 9-15.	1.7	4
158	Analysis of the occurrence and clinical significance of thrombocytopenis with c7E3 (abciximab) in the EPIC trial. <i>Journal of the American College of Cardiology</i> , 1996, 27, 82.	2.8	3
159	Prevention of arterial and venous thrombotic events in symptomatic peripheral arterial disease patients after lower extremity revascularization in the VOYAGER PAD trial: Dual anticoagulant/antiplatelet regimen vs antiplatelet therapy alone. <i>Journal of Thrombosis and Haemostasis</i> , 2022, 20, 1193-1205.	3.8	3
160	Improvement in walking impairment following surgical and endovascular revascularization: Insights from VOYAGER PAD. <i>Vascular Medicine</i> , 2022, 27, 343-349.	1.5	3
161	Vascular access site complications during angioplasty with glycoprotein IIb/IIIa receptor inhibition in the IMPACT II trial. <i>Journal of the American College of Cardiology</i> , 1996, 27, 360.	2.8	2
162	CHARACTERISTICS AND OUTCOMES OF PATIENTS WITH ATRIAL FIBRILLATION AND SIGNIFICANT VALVULAR LESIONS: EXPERIENCE FROM THE ROCKET AF TRIAL. <i>Journal of the American College of Cardiology</i> , 2013, 61, E282.	2.8	2

#	ARTICLE	IF	CITATIONS
163	Patient-Reported Satisfaction and Study Drug Discontinuation: Post-Hoc Analysis of Findings from ROCKET AF. <i>Cardiology and Therapy</i> , 2019, 8, 283-295.	2.6	2
164	Regional, sex, and age differences in diagnostic testing among participants in the NAVIGATE-ESUS trial. <i>International Journal of Stroke</i> , 2021, 16, 55-62.	5.9	2
165	Rivaroxaban in Patients With Recent Peripheral Artery Revascularization and Renal Impairment. <i>Journal of the American College of Cardiology</i> , 2021, 78, 757-759.	2.8	2
166	Response by Piccini et al to Letters Regarding Article, “Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation” • <i>Circulation</i> , 2016, 134, e7-8.	1.6	1
167	Pharmacotherapy for diabetes and stroke risk: Results from ROCKET AF. <i>Heart Rhythm</i> O2, 2021, 2, 215-222.	1.7	1
168	Clinical factors associated with peripheral artery disease in patients with documented coronary artery disease: A post hoc analysis of the COMPASS trial. <i>Atherosclerosis</i> , 2021, 331, 38-44.	0.8	1
169	Abstract 14170: Reduction in Venous Thromboembolism With Rivaroxaban versus Placebo in Peripheral Artery Disease After Lower Extremity Revascularization: Insights From VOYAGER PAD. <i>Circulation</i> , 2020, 142, .	1.6	1
170	Comment on model-based meta-analysis to evaluate optimal doses of direct oral factor Xa inhibitors in atrial fibrillation patients. <i>Blood Advances</i> , 2018, 2, 3193-3195.	5.2	0
171	Termination Based on Event Accrual in Per Protocol Versus Intention to Treat in the ROCKET AF Trial. <i>Journal of the American Heart Association</i> , 2021, 10, e022485.	3.7	0
172	Bleeding Indicators and Wound Complications with Ximelagatran and Warfarin after TKR: Findings from 3 Clinical Trials.. <i>Blood</i> , 2004, 104, 1771-1771.	1.4	0